Project Grant R21CA295643
Award Date
1/1/25
Completion Date
12/31/26
Dollars Obligated
$236K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700.00 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at overcoming rapid resistance to targeted therapies in colorectal cancer. The key products and services to be delivered under this 2-year award include: Evaluating how intrinsic tumor features modulate the development of resistance to targeted therapies in colorectal cancer through analysis of...
This National Cancer Institute (CFDA 93.396 Cancer Biology Research) Project Grant award of $560,297 to the Icahn School of Medicine at Mount Sinai supports research to functionally characterize oncofetal stem cells (ONFSCs) in colorectal cancer (CRC). The key objectives are to: Generate phenotypic transcriptional reporters to track the dynamics of LGR5+ cancer stem cells (CSCs) and ONFSCs, and use these to dissect the functional interplay between these stem cell populations. Employ a multi-omic...
This Project Grant award, funded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), aims to develop a first-of-its-kind intervention against colorectal cancer (CRC) associated with colibactin-producing bacteria. The $627,422 award to the Regents of the University of Michigan will support a 5-year research effort to engineer E. coli bacteria to display an anti-toxin enzyme that neutralizes the carcinogenic colibactin. The project will optimize the surface display of this...
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to Beth Israel Deaconess Medical Center, Inc. (BIDMC) provides $749,474 to conduct research aimed at understanding the underlying mechanisms of failed inflammation resolution in chemical-induced cancers. The research will focus on profiling lipid autacoid mediators, including eicosanoids and specialized pro-resolving mediators (SPMs), as well as cytokines, to evaluate their role in regulating...
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Targeting the Evolving Immunopeptidome of Metastatic Colorectal Cancer," aims to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic lesion patient-derived organoids (PDOs) through mass spectrometry. This will identify conserved...
This Project Grant award, totaling $482,236 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to develop a new targeted therapy for patients with HER2-low metastatic colorectal cancer (mCRC). The principal investigator at the Sloan-Kettering Institute for Cancer Research will conduct a Phase 2 clinical trial to evaluate the safety and efficacy of combining the antibody-drug conjugate trastuzumab deruxtecan (T-DXD) with the...
This $107,071 Project Grant award from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research by Rockefeller University to investigate the role of inter-organellar communication in metabolic reprogramming of colorectal cancer. The project aims to elucidate the molecular mechanisms by which tumor hypoxia modulates endoplasmic reticulum-mitochondria contact sites, a critical feature of cellular metabolism, and how this impacts colorectal cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop a novel nanocarrier-based immunochemotherapy for the treatment of metastatic colorectal cancer (mCRC). The key products and services to be delivered include: Developing and characterizing a nanoparticle carrier capable of co-delivering small interfering RNA targeting the IRHOM1 protein and a prodrug conjugate of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611.00 to the University of Texas Health Science Center at Houston to investigate the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives are to: Characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids. Develop and evaluate highly potent GPR56-targeted...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...